When managing idiopathic pulmonary fibrosis (IPF), there are impactful nonpharmacologic interventions and referrals that can improve patient outcomes. Read an expert’s commentary on strategies to improve quality of life and outcomes in patients with IPF.
This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Genentech, a member of the Roche Group.
Dr Kershaw: consulting fees: Boehringer Ingelheim
© 2021 Practicing Clinicians Exchange. All Rights Reserved. 102621BI-CT